• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

    11/14/23 5:25:00 PM ET
    $ASH
    $MRK
    Specialty Chemicals
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASH alert in real time by email

    WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023.  Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India.

    As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annual Stockholders Meeting in January 2024. With the addition of Chattopadhyay, Ashland temporarily increases the size of the Board to 11 members until the next Annual Stockholders Meeting in January 2024.

    Chattopadhyay is a broadly experienced global executive who brings strong industry leadership in manufacturing, distribution, supply chain, and more. He has led complex operations that span 22 countries including cutting-edge manufacturing technology while successfully navigating the ever-changing, globally complex, and heavily regulated industry of biopharmaceuticals.

    "I am pleased to welcome Sanat as a new director to the Ashland Board," said Guillermo Novo, chair and chief executive officer, Ashland. "As we continue to execute our strategy and increase our focus and scale in pharmaceuticals, personal care and coatings, I am confident Sanat will provide important perspectives for our team. And once again, I want to thank Jay and Brendan for their dedicated service to the Board."

    To learn more, visit investor.ashland.com

    About Ashland 

    Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environment, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 3,800 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more. 

    ™ Trademark, Ashland or its subsidiaries, registered in various countries.

    FOR FURTHER INFORMATION:

    Investor Relations:Media Relations:
    Seth A. MrozekCarolmarie C. Brown
    +1 (302) 594-5010+1 (302) 995-3158
    samrozek@ashland.comccbrown@ashland.com

    Attachment

    • Ashland_announces_new_board_member_20231114


    Primary Logo

    Get the next $ASH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASH
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    5/6/2026$125.00Neutral
    Citigroup
    Ashland Inc.
    $ASH
    5/6/2026$75.00Neutral → Buy
    Seaport Research Partners
    Merck & Company Inc.
    $MRK
    2/25/2026$142.00Outperform
    RBC Capital Mkts
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    Merck & Company Inc.
    $MRK
    1/8/2026$135.00Peer Perform → Outperform
    Wolfe Research
    Merck & Company Inc.
    $MRK
    12/18/2025$130.00Market Perform → Outperform
    BMO Capital Markets
    Ashland Inc.
    $ASH
    12/15/2025$71.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $ASH
    $MRK
    SEC Filings

    View All

    SEC Form 11-K filed by Merck & Company Inc.

    11-K - Merck & Co., Inc. (0000310158) (Filer)

    6/24/26 3:12:00 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 11-K filed by Merck & Company Inc.

    11-K - Merck & Co., Inc. (0000310158) (Filer)

    6/24/26 3:08:47 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 11-K filed by Merck & Company Inc.

    11-K - Merck & Co., Inc. (0000310158) (Filer)

    6/24/26 3:05:10 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Warden Kathy J

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    6/2/26 4:14:55 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Karsanbhai Surendralal Lanca

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    6/2/26 3:31:57 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Coe Mary Ellen

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    6/2/26 2:26:39 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

    First approval of PD‑1 inhibitors in combination with a Trop-2-directed antibody-drug conjugate (ADC) in advanced TNBC, marking a potentially practice‑changing treatment option Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead’s Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (Com

    6/25/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Quest to Repair What Multiple Sclerosis Takes Away

    AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (profile) is determin

    6/24/26 8:30:00 AM ET
    $QNTM
    $NVS
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

    AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response ("DDR") inhibitors, a category of drugs that work by blocking cancer cells' capacity to fix their own damaged DNA, are growing well beyond the poly ADP ribose polymerase ("PARP") inhibitor that first defined the category. DDR-inhibiting therapies generated an estimated $7 billion-plus in worldwide sales in 2025, and the wider oncology, diagnostics and precision medicine markets are expected to approach about $750 billion by 2030. A fresh wave of inhibitor classes is now taking shape as the next major opportunity.

    6/24/26 8:30:00 AM ET
    $MRK
    $PFE
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ASH
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on Merck with a new price target

    Citigroup resumed coverage of Merck with a rating of Neutral and set a new price target of $125.00

    5/6/26 7:35:08 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ashland upgraded by Seaport Research Partners with a new price target

    Seaport Research Partners upgraded Ashland from Neutral to Buy and set a new price target of $75.00

    5/6/26 7:31:43 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    RBC Capital Mkts initiated coverage on Merck with a new price target

    RBC Capital Mkts initiated coverage of Merck with a rating of Outperform and set a new price target of $142.00

    2/25/26 7:52:46 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chair of the Board and CEO Novo Guillermo bought $2,010,327 worth of shares (31,294 units at $64.24) (SEC Form 4)

    4 - ASHLAND INC. (0001674862) (Issuer)

    2/3/25 4:30:05 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    Ashland Board appoints Bertrand Loy as new director

    WILMINGTON, Del., May 18, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) is announcing the appointment of Bertrand Loy to its board of directors, effective May 15, 2026. Loy currently serves as a director and the executive chair of Entegris Inc. (NASDAQ:ENTG), a leading supplier of advanced materials and process solutions for the semiconductor and high-technology industries and previously served as Entegris' president and chief executive officer. He will serve on the board's audit and governance and nominating committees, also effective as of May 15, 2026. With the addition of Loy and in anticipation of potential director retirements under the board's retirement and resignation policy,

    5/18/26 7:00:00 AM ET
    $ASH
    $ENTG
    Specialty Chemicals
    Consumer Discretionary
    Plastic Products
    Industrials

    Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called "Bad" Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke

    The Yankees, Red Sox, Phillies, Braves, Astros, Cardinals, Giants, Padres, and Angels are joining Merck to help educate fans about high bad cholesterol and how it may increase the risk of heart attack or stroke Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced a collaboration with nine professional baseball teams and former professional baseball players to launch the Playing with Heart educational program to help educate adults about the importance of knowing their low-density lipoprotein cholesterol (LDL-C), called "bad" cholesterol, number and the potential increased risk of heart attack or stroke. Playing with Heart connects Merck's commitment to

    4/28/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Financials

    Live finance-specific insights

    View All

    Ancora Releases Presentation Highlighting the Opportunity for a Value-Maximizing, Competitive Sale Process at Ashland Inc.

    Believes Ashland's High-Margin, Strategically Scarce Assets Are Being Undervalued by the Public Markets in the Face of Near-Term Growth and Execution Issues Urges Ashland's Board to Conduct a Full Review of Strategic Alternatives, Including Evaluating Sale Options Following Apparent Interest from Standard Industries as Well as Other Strategic and Private Equity Buyers Releases Presentation Outlining How a Sale Could Yield ~$76 Per Share or More, Representing a More Than 33% Premium and Likely the Best Risk-Adjusted Path Forward Ancora Holdings Group, LLC (collectively with its affiliates, "Ancora") today released a presentation (available here) detailing what it believes is a near-ter

    6/9/26 4:05:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Merck Announces Third-Quarter 2026 Dividend

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the third quarter of 2026. Payment will be made on July 8, 2026, to shareholders of record at the close of business on June 15, 2026. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intens

    5/26/26 1:28:00 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ashland board authorizes quarterly dividend

    WILMINGTON, Del., May 05, 2026 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.42 cents per share on the company's common stock which represents a 1.2 percent increase from the previous quarter. The dividend will be payable on June 15, 2026, to stockholders of record at the close of business on June 1, 2026. As of April 30, 2026, there were 45,788,007 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of co

    5/5/26 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ashland Inc.

    SC 13G - ASHLAND INC. (0001674862) (Subject)

    11/12/24 11:54:03 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Ashland Inc.

    SC 13G/A - ASHLAND INC. (0001674862) (Subject)

    7/10/24 1:14:41 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SC 13D/A filed by Ashland Inc. (Amendment)

    SC 13D/A - ASHLAND INC. (0001674862) (Subject)

    4/25/24 4:15:12 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary